Skip to content

EBITDA at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Eli Lilly logo
Eli LillyLLY
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Calculated from AnaptysBio, Inc.’s reported figures.

$34.6Mebit+
$130.0KDepreciation Depletion & Amortization
=-$34.51M

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s EBITDA?
AnaptysBio, Inc. (ANAB) reported EBITDA of -$34.51M in Q1 2026.
How has AnaptysBio, Inc.'s EBITDA changed year-over-year?
AnaptysBio, Inc.'s EBITDA decreased by 26.0% year-over-year, from -$27.39M to -$34.51M.
What is the long-term trend for AnaptysBio, Inc.'s EBITDA?
Over 4 years (2021 to 2025), AnaptysBio, Inc.'s EBITDA has grown at a -3.6% compound annual growth rate (CAGR), from -$56.2M to $48.46M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.